Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-30 07:30 |
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire »
|
French | 149.2 KB | ||
| 2025-06-30 07:30 |
Press release: Availability of the Q2 2025 Aide mémoire
|
English | 145.6 KB | ||
| 2025-06-30 07:00 |
Communiqué de presse : Le riliprubart obtient la désignation de médicament orph…
|
French | 216.7 KB | ||
| 2025-06-30 07:00 |
Press Release: Riliprubart granted orphan drug designation in Japan for chronic…
|
English | 205.5 KB | ||
| 2025-06-27 22:52 |
FORM 11-K
|
English | 339.7 KB | ||
| 2025-06-27 22:49 |
FORM 11-K
|
English | 163.2 KB | ||
| 2025-06-25 07:00 |
Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux…
|
French | 209.4 KB | ||
| 2025-06-25 07:00 |
Press Release: Riliprubart earns orphan drug designation in the US for antibody…
|
English | 205.3 KB | ||
| 2025-06-24 14:31 |
6-K
|
English | 93.2 KB | ||
| 2025-06-24 04:36 |
Sanofi : Déclaration des transactions sur actions propres
|
French | 3.0 MB | ||
| 2025-06-23 07:00 |
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CH…
|
French | 232.8 KB | ||
| 2025-06-23 07:00 |
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transp…
|
English | 228.7 KB | ||
| 2025-06-20 07:00 |
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médic…
|
French | 225.5 KB | ||
| 2025-06-20 07:00 |
Press Release: Dupixent approved in the US as the only targeted medicine to tre…
|
English | 212.2 KB | ||
| 2025-06-18 12:43 |
6-K
|
English | 22.0 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
